Companies: 48,686 Total Market Cap: 126722197829037.30

Pharming Group N.V.

AMS-PHARM
Healthcare Biotechnology
Rank #12006
Market Cap 604.29 M
Volume 1.62 M
Price 0.89
Change (%) 0.57%
Country or region Netherlands Netherlands

Pharming Group N.V.'s latest marketcap:

604.29 M

As of May 7, 2025, Pharming Group N.V.'s market capitalization has reached $604.29 M. According to our data, Pharming Group N.V. is the 12006th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 604.29 M
Revenue (ttm) 325.60 M
Net Income (ttm) -12,972,325.94
Shares Out 683.93 M
EPS (ttm) -0.02
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date May 8, 2025
Market Cap Chart
Data Updated: May 7, 2025

Pharming Group N.V.'s yearly market capitalization.

Pharming Group N.V. has seen its market value drop from €811.61 M to €532.78 M since 2020, representing a total decrease of 34.35% and an annual compound decline rate (CAGR) of 9.23%.
Date Market Cap Change (%)
May 7, 2025 €532.78 M -13.18%
December 31, 2024 €627.48 M -9.08%
December 29, 2023 €690.16 M -2.41%
December 30, 2022 €707.22 M 40.66%
December 31, 2021 €502.78 M -38.05%
December 31, 2020 €811.61 M

Company Profile

About Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company specializing in the development and commercialization of protein replacement therapies and precision medicines for rare diseases. The company operates in the United States, Europe, and internationally.

Key Products

  • RUCONEST – A recombinant C1 esterase inhibitor for treating acute hereditary angioedema (HAE) attacks in adults and adolescents.
  • Joenja (leniolisib) – An oral small molecule PI3Kẟ inhibitor for activated phosphoinositide 3-kinase delta syndrome.

Pipeline Development

The company is advancing OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for HAE treatment.

Strategic Collaborations

  • Development and license agreement with Novartis.
  • Strategic partnership with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.

Company Background

Founded in 1988, Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Frequently Asked Questions

As of May 7, 2025, Pharming Group N.V. (including the parent company, if applicable) has an estimated market capitalization of $604.29 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Pharming Group N.V. global market capitalization ranking is approximately 12006 as of May 7, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Netherlands
Founded 1988
IPO Date n/a
Employees 404
CEO Fabrice Chouraqui
Sector Healthcare
Industry Biotechnology
Address Darwinweg 24
Leiden, 2333 CR
Netherlands
People Also Watch
VRTX
450.03 0.57%
ASX-CSL
159.57 0.57%
REGN
558.52 0.57%
KRX-207940
772.52 0.57%